Everything below concerns Synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Freeze-dried solid, often hygroscopic |
| Solubility class | Freely soluble in water | Aqueous buffers used for stock solutions |
| Storage, dry powder | Minus 20 °C or colder | Recommended for long-term retention |
| Storage, solution | 2–8 °C or frozen | Avoid repeated freeze-thaw cycles |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity percentage plus mass confirmation |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
== See also == Mepolizumab, anti–IL-5 to treat chronic rhinosinusitis with nasal polyps Omalizumab, anti–immunoglobulin E to treat chronic rhinosinusitis with nasal polyps Tezepelumab, anti-thymic stromal lymphopoietin to treat chronic rhinosinusitis with nasal polyps
doi:10.1371/journal.pone.0010958. PMC 2881040. PMID 20532040. Sibuet, M.; Olu, K. (1998). "Biogeography, biodiversity and fluid dependence of deep-sea cold-seep communities at active and passive margins". Deep-Sea Research Part II: Topical Studies in Oceanography. 45 (1–3): 517–567. Bibcode:1998DSRII..45..517S. doi:10.1016/S0967-0645(97)00074-X. Vinn, O.; Hryniewicz, K; Little, C.T.S.; Nakrem, H.A. (2014). "A Boreal serpulid fauna from Volgian-Ryazanian (latest Jurassic-earliest Cretaceous) shelf sediments and hydrocarbon seeps from Svalbard". Geodiversitas. 36 (4): 527–540. doi:10.5252/g2014n4a2. S2CID 129587761. Retrieved 9 January 2014. Vinn, O.; Kupriyanova, E.K.; Kiel, S. (2013). "Serpulids (Annelida, Polychaeta) at Cretaceous to modern hydrocarbon seeps: Ecological and evolutionary patterns". Palaeogeography, Palaeoclimatology, Palaeoecology. 390: 35–41. Bibcode:2013PPP...390...35V. doi:10.1016/j.palaeo.2012.08.003. Retrieved 9 January 2014.
== Measurement == Formulas have been devised to estimate energy expenditure in humans, but they may not be accurate. Specifically they may not account for the effect of certain illnesses or the elderly. Not all formula are accurate in overweight or obese individuals. Traditional models for measuring human energy expenditure assumes that one's total daily energy expenditure (TDEE) is the simple additive sum of the measurement of each part of the body (e.g., resting metabolic rate, skeletal movement, and non-movement energy expenditures such as reproduction, digestion, immune system, etc.). Yet recent evidence suggests that the additive model may be accurate only up to an initial daily energy tipping point, after which the sum of the activities do not result in more energy expenditure, thus reflecting a constrained metabolic system. This is called the constrained daily energy expenditure model. Wearable devices can help estimate energy expenditure from physical activity but their accuracy varies.
Sources: en.wikipedia.org
The need for elevated temperatures and pressures leads to high energy consumption and high capital investment costs. Disposal of unwanted by-products may be difficult and/or expensive and hazardous solvents may be required. In stark contrast, enzymatic reactions are performed under mild conditions of temperature and pressure, in water as solvent, and exhibit very high rates and are often highly specific. Moreover, they are produced from renewable raw materials and are biodegradable. In addition, the mild operating conditions of enzymatic processes mean that they can be performed in relatively simple equipment and are easy to control. In short, they reduce the environmental footprint of manufacturing by reducing the consumption of energy and chemicals and concomitant generation of waste. In the production of fine chemicals, flavors and fragrances, agrochemicals and pharmaceuticals an important benefit of enzymes is the high degree of chemoselectivity, regioselectivity and enantioselectivity which they exhibit. Particularly, their ability to catalyze the formation of products in high enantiopurity, by an exquisite stereochemical control, is of the utmost importance in these industries. Notwithstanding all these desirable characteristic features of enzymes, their widespread industrial application is often hampered by their lack of long term operational stability and shelf-storage life, as well as by their cumbersome recovery and re-use. These drawbacks can be generally overcome by enzyme immobilization.
Serving as an assassin due to his complete immunity to neurotoxins, which he coats himself with in the form of a cologne-like aerosol, he views other humans with disdain and causes them to feel an inexplicable repulsion by his very presence. The concept is used during Ryan North's 2023 run on Fantastic Four as an existential threat towards the human population.
== Synthesis == The compound was first described in 1935 by Ferdinand Münz, who prepared the compound from ethylenediamine and chloroacetic acid. Today, EDTA is mainly synthesised from ethylenediamine (1,2-diaminoethane), formaldehyde, and sodium cyanide. This route yields the tetrasodium EDTA, which is converted in a subsequent step into the acid forms:
== Further reading == Feldman and Pike's Vitamin D (5th Edition) Volume One: Biochemistry, Physiology and Diagnostics; Editors: Hewison M, Bouillon R, Giovannucci E, Goltzman D, Meyer MB, Welsh J. Academic Press (October 2023) ISBN 978-0-32-391386-7 Feldman and Pike's Vitamin D (5th Edition) Volume Two: Diseases and Therapeutics; Editors: Hewison M, Bouillon R, Giovannucci E, Goltzman D, Meyer MB, Welsh J. Academic Press (January 2024) ISBN 978-0-32-391338-6 Dietary Reference Intakes for Vitamin D and Calcium Editors: Ross AC, Taylor CL, Yaktine AL, Del Valle HB. National Academies Press (US) (2011) ISBN 978-0-30-916394-1 Available from: Dietary Reference Intakes for Calcium and Vitamin D doi: 10.17226/13050
Sources: en.wikipedia.org
==== Marketed ==== Dextromethorphan (DXM; Robitussin) Dextropropoxyphene (Darvon) Dimenhydrinate (Dramamine) Diphenhydramine (Benadryl) Mepyramine (pyrilamine) (Anthisan) Mifepristone (Korlym, Mifeprex)
=== Relaxing temperature requirements === The typical recommendation of storage 2–8 °C (36–46 °F), often worded as a "requirement" on the label, is mainly derived from the cold chain guideline of the Expanded Program on Immunization as a matter of tradition. Vaccines are not routinely tested for their stability at higher temperatures. In places with unreliable power supply, this leads to doses of vaccines that are potentially still effective being written off when the cold chain is interrupted, or no attempt to supply the vaccine to be even done due to the perceived cost of the cold chain. Similarly, many vaccines carry an unnecessary "do not freeze" instruction. Both WHO and PATH have published compilations on the stability of vaccines beyond the recommended temperature range, specifically for heat and freezing. Studies have found that when vaccines are allowed to go outside the cold chain (OCC), vaccination coverage are increased, sometimes by 2–3 fold. The WHO has since formalized this approach as controlled temperature chain (CTC), where vaccines able to withstand room temperatures (up to 40 °C (104 °F) for days) and used for campaigns or special delivery (not routine immunization) are considered for approval. MenAfriVac was licensed (prequalified) for CTC in 2012 and has seen great success in the African meningitis belt. As of 2021, the only other CTC-prequalified vaccine is Gardasil which is yet to see wide use. PCV13 was CTC approved until 2016 when it was removed to allow consistent labeling.
The isotope effect associated with transamination also makes amino acid nitrogen isotopes a useful tool to study the structure of food webs. Repeated transamination by consumers results in a predictable increase in the abundance of 15N as amino acids are transferred up food chains. Together, these application, among others in ecology, demonstrate the utility of stable isotopes as tracers of environmental processes that are difficult to measure directly.
Sources: en.wikipedia.org
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.
Reverse-phase liquid chromatography is used to assess purity, and mass spectrometry confirms molecular mass. Together these two checks form the most widespread approach. Some laboratories add amino acid analysis for further verification.
Yes. The peptide is freely soluble in water and in aqueous buffers, so reconstitution does not require an organic solvent. Stock solutions are usually prepared in water or a mild buffer. Exact handling depends on the intended downstream application.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.